Anti-dsDNA: choice of assay in relation to clinical value
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Antibodies to DNA are quite specific for systemic lupus erythematosus (SLE) and occur in the majority of SLE patients. Therefore, their detection is an important diagnostic aid to the clinician. Detection of anti-dsDNA may precede the diagnosis of SLE by more than a year. Fluctuations in the level of anti-dsDNA in an individual patient may give important information on the clinical status of the patient. Four of the most important methods developed for the measurement of anti-dsDNA antibodies will be discussed in this paper: the Farr assay, the PEG assay, the indirect immunofluorescence test on Crithidia luciliae and the ELISA. They will also be compared with one commercially available (Farr) assay, the Amersham anti-dsDNA kit. Each method, detects a part of the spectrum of anti-dsDNA antibodies produced by a patient. The Farr assay is the most specific for SLE; however, milder forms of the disease in which patients have only low avidity anti-dsDNA may easily be missed by this technique. Clinically, high avidity anti-dsDNA is related more frequently to the occurrence of nephritis, whereas low avidity anti-dsDNA antibodies are found more often in patients with central nervous system involvement. Traditionally, SLE is considered an immune-complex disease, in which inflammatory processes are initiated by local deposition of DNA/anti-dsDNA complexes. More recently, a major role was thought to be played by crossreactions of anti-dsDNA with tissue constituents. Our current view, ho…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a consequence, not all assays will generate similar values, even after standardization [80].”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [80]
In the citing paper
“As the Farr assay includes ammonium sulphate precipitation at high salt concentrations, a condition that dissociates dsDNA-anti-dsDNA complexes of low avidity, 4 this assay detects only antibodies with high avidity. 5”
In the citing paper
“High avidity anti-dsDNA antibodies are more specific for SLE than those with low avidity 5”
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519 · cited 1×
“General comparison of the five anti-dsDNA assays using sera of patients with SLE defned according to the revised criteria of the American Rheumatism Association [ 33 ], leads to high levels of correlations between the various assays.”
MethodAntinuclear Antibodies: Diagnostic Markers for Autoimmune Diseases and Probes for Cell Biology
Tan, E. M. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60641-0 · Cited by 1,514 · cited 1×
“SLE has been termed an autoimmune disease because many antibodies detected in the circulation of such patients are directed to autoantigens, in particular nucleic acids and proteins associated with nucleic acids [2, 3].”
BackgroundTer Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C., & Kallenberg, C. G. M. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330505 · Cited by 572 · cited 1×
“An illustration of such a pattern is given in Fig. 3. These observations have been confirmed recently by Ter Borg et al. [ 46 ].”
BackgroundAarden, L. A., Groot, E. R. D., & Feltkamp, T. E. W. (1975) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1975.tb29197.x · Cited by 563
Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids.
Lafer, E. M., Rauch, J., Andrzejewski, C., Mudd, D., Furie, B., Furie, B., Schwartz, R. S., & Stollar, B. D. (1981) · The Journal of experimental medicine · doi:10.1084/jem.153.4.897 · Cited by 536
ANTIBODIES TO POLYNUCLEOTIDES IN HUMAN SERA: ANTIGENIC SPECIFICITY AND RELATION TO DISEASE
Koffler, D., Carr, R., Agnello, V., Thoburn, R., & Kunkel, H. G. (1971) · The Journal of Experimental Medicine · doi:10.1084/jem.134.1.294 · Cited by 510
Polyspecificity of Monoclonal Lupus Autoantibodies Produced by Human-Human Hybridomas
Shoenfeld, Y., Rauch, J., Massicotte, H., Datta, S. K., André-Schwartz, J., Stollar, B. D., & Schwartz, R. S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198302243080802 · Cited by 450 · cited 1×
“Monoclonal antibodies to DNA were often found to crossreact with structures such as phospholipids, proteoglycans or other polynegative molecules [5, 6, 8, 51, 52].”
BackgroundRivera, J. A. (1971) · Military Medicine · doi:10.1093/milmed/136.1.96a · Cited by 446
Winfield, J. B., Faiferman, I., & Koffler, D. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108626 · Cited by 405
Wold, R. T., Young, F. E., Tan, E. M., & Farr, R. S. (1968) · Science · doi:10.1126/science.161.3843.806 · Cited by 378 · cited 1×
“Farr assay. The Farr assay employs ammonium sulphate precipitation to separate DNA/anti-dsDNA complexes from free (radiolabeled) DNA [ 21 ].”
Method
Research works printed but not linked: 4
- Aarden LA, Smeenk R (1982) Immunochemical properties of antibodies to DNA and their influence on detection methods. In: Kalden JR, Feltkamp TEW (eds) Antibodies to nuclear antigens. Excerpta Medica, Amsterdam, pp 23?28
- Izui S, Lambert PH, Miescher PA (1977) Failure to detect circulating DNA/anti-DNA complexes by four radioimmunochemical methods in patients with SLE. Clin Exp Immunol 30:384?392
- Faaber P, Capel PJA, Rijke GPM, Vierwinden G, Putte LBA van de, Koene RAP (1984) Crossreactivity of anti-DNA antibodies with proteoglycans. Clin Exp Immunol 55:502?510
- Faaber P, Rijke GPM, Smeenk RJT, Capel PJA, Putte LBA van de, Berden JHM (1985) Crossreactivity of anti-DNA antibodies: a new clue for the pathogenesis of SLE? In: Peeters H (ed) Protides of the biological fluids, 33rd edn. Pergamon, London, pp 405?408
Cited by
Hahn, B. H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805073381906 · Cited by 682
Linnik, M. D., Hu, J. Z., Heilbrunn, K. R., Strand, V., Hurley, F. L., Joh, T., & LJP 394 Investigator Consortium (2005) · Arthritis & Rheumatism · doi:10.1002/art.20980 · Cited by 209
Cardiel, M. H., Tumlin, J. A., Furie, R. A., Wallace, D. J., Joh, T., & Linnik, M. D. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23673 · Cited by 147
Development of Anti‐dsDNA Autoantibodies Prior to Clinical Diagnosis of Systemic Lupus Erythematosus
Arbuckle, M. R., James, J. A., Kohlhase, K. F., Rubertone, M. V., Dennis, G. J., & Harley, J. B. (2001) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2001.00959.x · Cited by 130
Haugbro, K., Nossent, J. C., Winkler, T., Figenschau, Y., & Rekvig, O. P. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.016303 · Cited by 113
Bizzaro, N., Tozzoli, R., Tonutti, E., Piazza, A., Manoni, F., Ghirardello, A., Bassetti, D., Villalta, D., Pradella, M., & Rizzotti, P. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00140-9 · Cited by 105
Rekvig, O., & Nossent, J. C. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10739 · Cited by 101
Werwitzke, S., Trick, D., Kamino, K., Matthias, T., Kniesch, K., Schlegelberger, B., Schmidt, R. E., & Witte, T. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21379 · Cited by 98
The anti-DNA antibody: origin and impact, dogmas and controversies
Rekvig, O. P. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.69 · Cited by 98
Mummert, E., Fritzler, M. J., Sjöwall, C., Bentow, C., & Mahler, M. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.05.014 · Cited by 86
Monoplex and multiplex immunoassays: approval, advancements, and alternatives
Ahsan, H. (2021) · Comparative Clinical Pathology · doi:10.1007/s00580-021-03302-4 · Cited by 93
Review : Serological markers of disease activity in systemic lupus erythematosus
Spronk, P. E., Limburg, P. C., & Kallenberg, C. G. (1995) · Lupus · doi:10.1177/096120339500400202 · Cited by 71
Antico, A., Platzgummer, S., Bassetti, D., Bizzaro, N., Tozzoli, R., Villalta, D., & Study Group on Autoimmune Diseases of the Italian Society of Laboratory Medicine (SIMeL) (2010) · Lupus · doi:10.1177/0961203310362995 · Cited by 70
Grootscholten, C., Dieker, J. W. C., McGrath, F. D., Roos, A., Derksen, R. H. W. M., van der Vlag, J., Daha, M. R., & Berden, J. H. M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.065425 · Cited by 66
Self-citationAnti-C1q Antibodies as a Follow-Up Marker in SLE Patients
Bock, M., Heijnen, I., & Trendelenburg, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123572 · Cited by 64
“antibodies are more specific since they better correlate with the occurrence of lupus nephritis [33].”
BackgroundReview: immunoassays in DNA damage and instability detection
Boguszewska, K., Szewczuk, M., Urbaniak, S., & Karwowski, B. T. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03239-6 · Cited by 49
Anti‐ribosomal P protein: a novel antibody in autoimmune hepatitis
Calich, A. L., Viana, V. S. T., Cançado, E. L. R., Tustumi, F., Terrabuio, D. R. B., Leon, E. P., Silva, C. A., Borba, E. F., & Bonfá, E. (2013) · Liver International · doi:10.1111/liv.12155 · Cited by 43
“The exclusion criteria were the presence of a definite SLE diagnosis and/or the presence of specific disease-related antibodies (anti-dsDNA and anti-Sm) (18, 19).”
BackgroundMähler, M., & Dervieux, T. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205324 · Cited by 43
Rekvig, O. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569234 · Cited by 42
Anti-DNA antibodies - overview of assays and clinical correlations
Rahman, A., & Hiepe, F. (2002) · Lupus · doi:10.1191/0961203302lu313rp · Cited by 42
Detection of antibodies to dsDNA: an overview of laboratory assays
Rouquette, A., & Desgruelles, C. (2006) · Lupus · doi:10.1191/0961203306lu2324oa · Cited by 39
Werle, E., Blazek, M., & Fiehn, W. (1992) · Lupus · doi:10.1177/096120339200100606 · Cited by 39
Hung, W. T., Chen, Y., Jl, L., Chen, H., Chen, Y., Dy, C., Hsieh, C., & Wen, M.-C. (2011) · Lupus · doi:10.1177/0961203311417033 · Cited by 38
Clinical evaluation of a new automated anti-dsDNA fluorescent immunoassay
Hernando, M., González, C., Sánchez, A., Guevara, P., Navajo, J. A., Papisch, W., & González-Buitrago, J. M. (2002) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2002.185 · Cited by 35
“5) between different methods was obtained (11, 12) but in others there was a better concordance (13, 14).”
MethodDerksen, R. H. W. M., Bast, E. J. E. G., Strooisma, T., & Jacobs, J. W. G. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.12.1099 · Cited by 33
Laboratory evaluation of anti-dsDNA antibodies.
Cockx, M., Van Hoovels, L., De Langhe, E., Lenaerts, J., Thevissen, K., Persy, B., Bonroy, C., Vercammen, M., & Bossuyt, X. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.12.029 · Cited by 30
Canine systemic lupus erythematosus: New insights and their implications
Jones, D. (1993) · Journal of Comparative Pathology · doi:10.1016/s0021-9975(08)80286-1 · Cited by 29
Hylkema, M. N., van Bruggen, M. C. J., ten Hove, T., de Jong, J., Swaak, A. J. G., Berden, J. H. M., & Smeenk, R. J. T. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.1999.0354 · Cited by 28
Self-citationConrad, K., Ittenson, A., Reinhold, D., Fischer, R., Roggenbuck, D., Büttner, T., Bosselmann, H., Steinbach, J., & Schößler, W. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04801.x · Cited by 27
Quantitation of Autoantibodies in Systemic Autoimmune Diseases: Clinically Useful?
Kallenberg, C., Stegeman, C. A., Bootsma, H., Bijl, M., & Limburg, P. C. (2006) · Lupus · doi:10.1191/0961203306lu2323oa · Cited by 26
Detection of restricted junctional diversity of peripheral T cells in SLE patients by spectratyping
Kolowos, W., i, M. H., Ponner, B. B., Voll, R. E., Kern, P., Frank, C. H. N., & Kalden, J. (1997) · Lupus · doi:10.1177/096120339700600904 · Cited by 25
Miyawaki, S., Nishiyama, S., Aita, T., & Yoshinaga, Y. (2012) · Modern Rheumatology · doi:10.1007/s10165-012-0707-9 · Cited by 18
Gallium-67 scintigraphy to predict response to therapy in active lupus nephritis.
Lin, W., Lan, J., & Wang, S. (1998) · PubMed · Cited by 18
Bauer, C.-J., Karakostas, P., Weber, N., Behning, C., Stoffel‐Wagner, B., Brossart, P., Dolscheid‐Pommerich, R., & Schäfer, V. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1305865 · Cited by 21
“This observation has also initiated the discussion whether some test systems (with superior speci fi city) should be used preferably for screening and fi rst diagnosis, while others (with superior sensitivity) should then be used for follow-up assessments and fl are detection (8, 16, 20, 21).”
MethodAnti-DNA antibodies as early predictor for disease exacerbations in SLE: Guideline for treatment?
Spronk, P. E., Bootsma, H., & Kallenberg, C. G. M. (1998) · Clinical Reviews in Allergy & Immunology · doi:10.1007/bf02737631 · Cited by 16
Yuan, W., Cao, H., Wan, P., Shi, R., Zhou, S., & Zheng, J. (2019) · Lupus · doi:10.1177/0961203319877243 · Cited by 15
Gene immunization may induce secondary antibodies reacting with DNA
Isaguliants, M. G., Iakimtchouk, K., Petrakova, N. V., Yermalovich, M. A., Zuber, A. K., Kashuba, V. I., Belikov, S. V., Andersson, S., Kochetkov, S. N., Klinman, D. M., et al. (2003) · Vaccine · doi:10.1016/j.vaccine.2003.09.033 · Cited by 15
“UV-DNA ELISA allowed sensitive detection of anti-DNA Ig(G, A and M) antibodies in the sera of 100% (20/20) of SLE patients known to be positive for dsDNA antibodies in the Crithidia immunofluorescence test considered to be 100% specific [25] (Fig.”
BackgroundCardiel, M. H. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.1.77 · Cited by 15
“High titres of anti-dsDNA antibodies in SLE patients usually correlate with active renal disease, especially glomerulonephritis [10-12].”
BackgroundWasmuth, J., Grün, B., Terjung, B., Homrighausen, A., & Spengler, U. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.037960 · Cited by 13
“The Farr RIA is assumed to meet this need best (4, 5).”
BackgroundYu, L., Wang, J., O’Dell, J. R., Oates, J. C., Arend, W. P., & Eisenbarth, G. S. (2007) · PubMed · Cited by 13
Kinetics of biomolecular interactions
George, A. J. T., Gallop, J. L., & Rashid, M. (1997) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.7.9.947 · Cited by 12
(2011) · Springer eBooks · doi:10.1007/springerreference_31820 · Cited by 12
Chen, C.-Y., Tseng, H.-M., Chen, L.-C., Tsao, C.-H., Kuo, M.-L., Ou, L.-S., & Huang, J.-L. (2003) · Lupus · doi:10.1191/0961203303lu331oa · Cited by 11
Malkiel, S., & Diamond, B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801917-7.00024-3 · Cited by 10
Targeting of B cells in SLE: rationale and therapeutic opportunities.
Silverman, G. J. (2006) · PubMed · Cited by 8
Measurement of antibodies to DNA
Smeenk, R. J. T. (1996) · Springer eBooks · doi:10.1007/978-94-011-1670-1_8 · Cited by 8
Self-citationAkikusa, J., & Choo, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24145-8.00010-7 · Cited by 7
Measurement of antibodies to DNA
Smeenk, R. J. T. (1993) · Springer eBooks · doi:10.1007/978-94-011-5444-4_8 · Cited by 7
Self-citationBizzaro, N., Mazzoni, A., Carbone, T., Cinquanta, L., Villalta, D., Radice, A., Pesce, G., Manfredi, M., & Infantino, M. G. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103604 · Cited by 7
Smeenk, R. J. T., & Feltkamp, T. E. W. (1998) · Elsevier eBooks · doi:10.1006/rwei.1999.0036 · Cited by 6
Self-citationAnti-DNA Antibodies: Structure, Regulation and Pathogenicity
Aranow, C. B., Zhou, D., & Diamond, B. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10014-2 · Cited by 4
Lewy, R. I., & Ezrailson, E. G. (1996) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-85226-8_36 · Cited by 4
Peeva, E., & Diamond, B. (2004) · Elsevier eBooks · doi:10.1016/b978-012433901-9/50013-2 · Cited by 3
Clinical evaluation of cobas core anti‐dsDNA EIA quant
González, C., Guevara, P., Berrocal, B. G., Navajo, J. A., & González‐Buitrago, J. M. (2004) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.20023 · Cited by 3
“While some studies (10,11) obtained a low correlation (o0.”
ResultAlba, P. B., Bertolaccini, M. L., & Khamashta, M. A. (2007) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.3.4.613 · Cited by 6
A fluorescence sedimentation assay for dsDNA antibodies
Duus, K., Draborg, A. H., Güven, E., Moreno, Y. M., Jacobsen, S., Nielsen, C. T., & Houen, G. (2017) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2017.1339232 · Cited by 3
Clinical aspects of antibodies to double-stranded DNA
Swaak, A. J. G., & Smeenk, R. J. T. (1996) · Springer eBooks · doi:10.1007/978-94-011-1670-1_38 · Cited by 3
Self-citationAutoantibodies to dsDNA, Ro/SSA, and La/SSB in systemic lupus erythematosus
Chien, J., & Lin, C. (2003) · Advances in clinical chemistry · doi:10.1016/s0065-2423(03)37008-8 · Cited by 4
Rekvig, O. P., & Tsokos, G. C. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.103990 · Cited by 3
McCloskey, L. J., Christner, P. J., Jacobs‐Kosmin, D., Jaskowski, T. D., Hill, H. R., Lakos, G., & Teodorescu, M. (2010) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.20358 · Cited by 3
“One study on 440 mixed SLE patients reported the sensitivity of the Farr assay at 95 and 99% SICC to be 72 and 56%, respectively (19), which is similar to our 76 and 57% and to the results from other previous studies (3).”
MethodResultKuntz, N. L., & Strober, J. B. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511974373.007 · Cited by 2
Rekvig, O. P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1580664 · Cited by 1
Anticorpo antiproteína P ribossomal em pacientes com hepatite autoimune
Calich, A. L. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2013.tde-20052013-100023
Évaluation du kit Diasorin Liaison® dsDNA pour la détection des anticorps anti-DNA natif
Rouquette, A. M., Desgruelles, C., Lependeven, C., & Abuaf, N. (2007) · Immuno-analyse & Biologie Spécialisée · doi:10.1016/j.immbio.2006.12.002
Interpretation of Serologic Testing in Glomerular Diseases
Liang, K. V., & Liang, K. P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4454-1_8
Laboratory findings and renal pathology in systemic lupus erythematosus
Lee, S. (2010) · The Korean Journal of Internal Medicine
Chabas, D., & Waubant, E. L. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511974373.004
Elewi, I. H., Al-Mugdadi, S. F. H., & Latef., Q. (2016) · International Journal of Advanced Research · doi:10.21474/ijar01/910
Rheumatologic and Connective Tissue Disorders in Pregnancy
Leguizamón, G. F., & Reece, E. A. (2007) · Wiley eBooks · doi:10.1002/9780470753293.ch51
Immunodiagnosis of Systemic Lupus Erythematosus (SLE) in a tertiary care hospital
Ragunathan, L., Chidambaram, A., Kannaiyan, K., & N, C. N. C. (2020) · Annals of Pathology and Laboratory Medicine · doi:10.21276/apalm.2718 · Cited by 1
“The ds- DNA antibodies level tend to fluctuate with the course of the disease[9] and may act as a predictor of disease activity and exacerbation.”
Drug History and SLE Laboratory Findings Among Iraqi Patients: A Hospital‐Based Study
Hashim, H. T., Al‐Obaidi, A. D., Al‐Obaidi, M. N., Ali, H. T., Sula, I., Alfaki, H., Elamin, A., Hermis, A. H., Othman, A., & Alhatemi, A. Q. M. (2025) · Health Science Reports · doi:10.1002/hsr2.70493
“Serological tests, such as the presence of autoantibodies in circulation, may be very helpful to the clinician [3].”
Rekvig, O. P. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104138
Metadata
- Authors
- Smeenk, R. J. T., van den Brink, H. G., Brinkman, K., Termaat, R. M., Berden, J. H. M., & Swaak, A. J. G.
- Affiliations
- Radboud University Nijmegen (NL)
- ORCID
- Brinkman, K.
- Venue
- Rheumatology International
- Published
- 1991-09
- Volume
- 11
- Issue
- 3
- Pages
- 101-107
- ISSN
- 0172-8172 (ISSN-L)
- 1437-160X
- OpenAlex
- W2058665079
- Cited by
- 75
- References
- 60
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 3 · 2012: 2
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Rheumatology International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- anti-dsDNA antibodies, systemic lupus erythematosus, Farr assay, indirect immunofluorescence, Crithidia luciliae, ELISA, lupus nephritis, central nervous system involvement, immune complexes, lupus diagnosis
- MeSH terms
- Antibodies, Antinuclear, DNA, Humans, Lupus Erythematosus, Systemic, Prognosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.